Compare · IQV vs NOTV
IQV vs NOTV
Side-by-side comparison of IQVIA Holdings Inc. (IQV) and Inotiv Inc. (NOTV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IQV and NOTV operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- IQV is the larger of the two at $34.42B, about 12349.4x NOTV ($2.8M).
- Over the past year, IQV is up 28.4% and NOTV is down 95.4% - IQV leads by 123.8 points.
- NOTV has been more active in the news (8 items in the past 4 weeks vs 6 for IQV).
- IQV has more recent analyst coverage (25 ratings vs 9 for NOTV).
- Company
- IQVIA Holdings Inc.
- Inotiv Inc.
- Price
- $206.22-2.02%
- $0.08-14.45%
- Market cap
- $34.42B
- $2.8M
- 1M return
- +15.18%
- -72.65%
- 1Y return
- +28.37%
- -95.43%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 6
- 8
- Recent ratings
- 25
- 9
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Inotiv Inc.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Latest IQV
- SEC Form 4 filed by Director Wims Morris Leslie
- SEC Form 4 filed by Director Goggins Colleen A
- SEC Form 4 filed by Director Fasano Jim
- SEC Form 4 filed by Director Danhakl John G
- IQVIA's Dr. Cynthia Verst Testifies Before Congressional Subcommittee on More Efficient Path to Early Clinical Development in the United States
- IQVIA to Announce Second-Quarter 2026 Results on July 28, 2026
- IQVIA downgraded by Morgan Stanley with a new price target
- Wiley and IQVIA Release Cross-Sector Report on AI's Promise and Pressure Points Across Healthcare Value Chain
- IQVIA Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- SEC Form 8-K filed by IQVIA Holdings Inc.
Latest NOTV
- Inotiv Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Inotiv Announces Confirmation of Plan of Reorganization
- Chief Financial Officer Taylor Beth A. covered exercise/tax liability with 5,864 shares, decreasing direct ownership by 4% to 139,616 units (SEC Form 4) (for tax liability)
- Chief Strategy Officer Sagartz John E covered exercise/tax liability with 6,071 shares, decreasing direct ownership by 0.83% to 729,626 units (SEC Form 4) (tax withholding)
- Chief Commercial Officer Hardy Adrian covered exercise/tax liability with 5,371 shares, decreasing direct ownership by 9% to 53,049 units (SEC Form 4) to satisfy withholding tax
- VP-Finance & Corp. Controller Freeman Jeffrey Brennan covered exercise/tax liability with 5,855 shares, decreasing direct ownership by 14% to 36,623 units (SEC Form 4) (tax withholding)
- EVP, GC, Sec'y & CCO Castetter Andrea covered exercise/tax liability with 5,800 shares, decreasing direct ownership by 11% to 49,200 units (SEC Form 4) (for tax liability)
- Chief Operating Officer Beattie John Gregory covered exercise/tax liability with 5,769 shares, decreasing direct ownership by 3% to 180,992 units (SEC Form 4) (withholding obligation)
- Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Inotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits